177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer

Axel Bräuer, Lena Sophie Grubert, Wolfgang Roll, +4

European Journal of Nuclear Medicine and Molecular Imaging

UrologyGenitourinary CancerMedicineRadiopharmaceutical TherapyProstatic Disease +3

Multispectral optoacoustic tomography of the human breast: characterisation of healthy tissue and malignant lesions using a hybrid ultrasound-optoacoustic approach

Anne E. Becker, Max Masthoff, Jing Claussen, +8

European Radiology

Human BreastMedical UltrasoundEngineeringMedical ImagingHealthy Tissue +9

Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA

Philipp Backhaus, F. Gierse, Matthias C. Burg, +18

European Journal of Nuclear Medicine and Molecular Imaging

Simultaneous FAPI PET/MRI Targeting the Fibroblast-Activation Protein for Breast Cancer

Philipp Backhaus, Matthias C. Burg, Wolfgang Roll, +8

Radiology

Multispectral Optoacoustic Tomography of Benign and Malignant Thyroid Disorders: A Pilot Study

Wolfgang Roll, Niklas Markwardt, Max Masthoff, +9

Journal of Nuclear Medicine

Thyroid NodulesFunctional BiomarkersMedical UltrasoundEngineeringHealth Sciences +12

TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma

Bastian Zinnhardt, Michael Müther, Wolfgang Roll, +16

Neuro-Oncology

Multispectral optoacoustic tomography of systemic sclerosis

Max Masthoff, Anne Helfen, Jing Claussen, +10

Journal of Biophotonics

Imaging temozolomide-induced changes in the myeloid glioma microenvironment

Claudia Foray, Silvia Valtorta, Cristina Barca, +11

Theranostics

Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving ¹⁷⁷Lu-PSMA-617 Radioligand Therapy

Katharina Kessel, Robert Seifert, Matthias Weckesser, +6

Theranostics

177Lu-DOTATATE Therapy in Radioiodine-refractory Differentiated Thyroid Cancer

Wolfgang Roll, Burkhard Riemann, Michael Schäfers, +2

Clinical Nuclear Medicine